Related News

No related news articles were found.

fluoropharma medical inc (FPMI) Related Businessweek News

No Related Businessweek News Found

fluoropharma medical inc (FPMI) Details

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with primary applications in the area of cardiology in the United States. The company’s product portfolio includes BFPET, an imaging agent that has completed Phase Ia clinical trials in stress-testing for patients with known or suspected coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase II clinical trials to assess myocardial metabolism for patients with CAD. It is also developing candidates for use in the detection and treatment of vulnerable plaque. The company has license agreement with Massachusetts General Hospital. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

FluoroPharma Medical, Inc. filed its 10-K on Mar 31, 2015 for the period ending Dec 31, 2014. In this report its auditor, Wolf & Company, P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.